

U.S. Patent Application No. 10/058,069
Attorney Ref. No.: 037003-0280727

I. AMENDMENT

IN THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-19. (Canceled)

20. (Currently amended) A kit useful for the treatment of a mammal suffering from or predisposed to a neoplastic disorder comprising at least one container having a dimeric antibody that binds specifically to TAG-72 deposited therein,:

which dimeric antibody comprises two antibodies that are non-covalently associated to form a tetravalent antibody dimer,

wherein each of the antibodies in the dimer comprises two antibody heavy chain polypeptides having the heavy chain variable region amino acid sequence shown in Figure 4A (SEQ ID NO: 7), and two antibody light chain polypeptides having the light chain variable region amino acid sequence shown in Figure 5A (SEQ ID NO: 9), and has two antigen-binding sites; that bind

~~wherein one or more of the antigen-binding sites of the tetravalent antibody dimer binds specifically to TAG-72; and~~

wherein a C_H2 domain is deleted from each of the four antibody heavy chain polypeptides in the dimeric antibody;

and further comprising a label or an insert indicating that said dimeric antibody may be used to treat said neoplastic disorder.

21-28. (Canceled)

29. (Currently amended) A dimeric antibody that binds specifically to TAG-72,

which dimeric antibody comprises two antibodies that are non-covalently associated to form a tetravalent antibody dimer,

wherein each of the antibodies in the dimer comprises two antibody heavy chain polypeptides having the heavy chain variable region amino acid sequence shown in Figure 4A (SEQ ID NO: 7), and two antibody light chain polypeptides having the light chain variable region amino acid sequence shown in Figure 5A (SEQ ID NO: 9), and has two antigen-binding sites; that bind

~~wherein one or more of the antigen-binding sites of the tetravalent antibody dimer binds specifically to TAG-72; and~~

U.S. Patent Application No. 10/058,069
Attorney Ref. No.: 037003-0280727

wherein a C_H2 domain is deleted from each of the four antibody heavy chain polypeptides in the dimeric antibody.

30-37. (Canceled)

38. (Previously presented) The dimeric antibody of claim 29 wherein said dimeric antibody is conjugated to a cytotoxic agent.

39. (Original) The dimeric antibody of claim 38 wherein said cytotoxic agent comprises a radioisotope.

40. (Original) The dimeric antibody of claim 39 wherein said radioisotope is selected from the group consisting of ⁹⁰Y, ¹²⁵I, ¹³¹I, ¹²³I, ¹¹¹In, ¹⁰⁵Rh, ¹⁵³Sm, ⁶⁷Cu, ⁶⁷Ga, ¹⁶⁶Ho, ¹⁷⁷Lu, ¹⁸⁶Re and ¹⁸⁸Re.

41-54. (Canceled)

55. (Currently amended) The kit of claim 20, wherein said antibody dimer ~~comprises is~~ a chimeric antibody comprising light and heavy chain variable region polypeptides of a ~~non-human antibody that bind specifically to TAG-72, and~~ human antibody constant regions.

56. (Previously presented) The kit of claim 20, wherein said antibody dimer comprises an antibody heavy chain polypeptide in which a C_H3 domain is fused directly to the hinge region.

57. (Previously presented) The kit of claim 20, wherein said antibody dimer comprises an antibody heavy chain polypeptide in which an amino acid spacer is inserted in place of a deleted C_H2 domain.

58-61. (Canceled)

62. (Previously presented) The kit of claim ~~61~~ 55, wherein said antibody dimer comprises four antibody heavy chain polypeptides having the heavy chain polypeptide amino acid sequence shown in Figure 4A (SEQ ID NO: 7), and four antibody light chain polypeptides having the light chain polypeptide amino acid sequence shown in Figure 5A (SEQ ID NO: 9).

63. (Previously presented) The kit of claim 20 wherein said neoplastic disorder is colon cancer.

64-67. (Canceled)

U.S. Patent Application No. 10/058,069
Attorney Ref. No.: 037003-0280727

68. (Currently amended) The dimeric antibody of claim 29, wherein said antibody dimer ~~comprises is~~ a chimeric antibody comprising ~~light and heavy chain variable region polypeptides of a non-human antibody that bind specifically to TAG-72, and~~ human antibody constant regions.

69. (Previously presented) The dimeric antibody of claim 29, wherein said antibody dimer comprises an antibody heavy chain polypeptide in which a C_H3 domain is fused directly to the hinge region.

70. (Previously presented) The dimeric antibody of claim 29, wherein said antibody dimer comprises an antibody heavy chain polypeptide in which an amino acid spacer is inserted in place of a deleted C_H2 domain.

71-74. (Canceled)

75. (Currently amended) The dimeric antibody of claim ~~74~~ 68, wherein said antibody dimer comprises four antibody heavy chain polypeptides having the heavy chain polypeptide amino acid sequence shown in Figure 4A (SEQ ID NO: 7), and four antibody light chain polypeptides having the light chain polypeptide amino acid sequence shown in Figure 5A (SEQ ID NO: 9).

76. (Previously presented) The dimeric antibody of claim 38, wherein said cytotoxic agent is selected from the group consisting of cytostatic agents, alkylating agents, antimetabolites, anti-proliferative agents, tubulin binding agents, hormones and hormone antagonists, anthracycline drugs, vinca drugs, mitomycins, bleomycins, cytotoxic nucleosides, pteridine drugs, diynes, podophyllotoxins, toxic enzymes, and radiosensitizing drugs.

77. (Previously presented) The dimeric antibody of claim 76, wherein said cytotoxic agent is selected from the group consisting of mechlorethamine, triethylenephosphoramide, cyclophosphamide, ifosfamide, chlorambucil, busulfan, melphalan, triaziquone, nitrosourea compounds, adriamycin, carminomycin, daunorubicin (daunomycin), doxorubicin, aminopterin, methotrexate, methopterin, mithramycin, streptonigrin, dichloromethotrexate, mitomycin C, actinomycin-D, porfiromycin, 5-fluorouracil, floxuridine, florafur, 6-mercaptopurine, cytarabine, cytosine arabinoside, podophyllotoxin, etoposide, etoposide phosphate, melphalan, vinblastine, vincristine, leurosine, vindesine, leurosine, taxol, taxane, cytochalasin B, gramicidin D, ethidium bromide, emetine, tenoposide, colchicin, dihydroxy anthracin dione, mitoxantrone, procaine, tetracaine, lidocaine, propranolol, puromycin, ricin subunit A, abrin, diphtheria toxin, botulinum, cyanginosins, saxitoxin, shigatoxin, tetanus,

U.S. Patent Application No. 10/058,069
Attorney Ref. No.: 037003-0280727

tetrodotoxin, trichothecene, verrucologen, corticosteroids, progestins, estrogens, antiestrogens, androgens, aromatase inhibitors, calicheamicin, esperamicins, and dynemicins.

78. (Previously presented) The dimeric antibody of claim 76, wherein said hormone or hormone antagonist is selected from the group consisting of prednisone, hydroxyprogesterone, medroprogesterone, diethylstilbestrol, tamoxifen, testosterone, and aminogluthetimide.

79. (Previously presented) The dimeric antibody of claim 38, wherein said cytotoxic agent is a prodrug selected from the group consisting of phosphate-containing prodrugs, thiophosphate-containing prodrugs, sulfate containing prodrugs, peptide containing prodrugs, β -lactam-containing prodrugs, optionally substituted phenoxyacetamide-containing prodrugs, optionally substituted phenylacetamide-containing prodrugs, 5-fluorocytosinem, and 5-fluorouridine prodrugs that can be converted to the more active cytotoxic free drug.

80. (New) A kit useful for the treatment of a mammal suffering from or predisposed to a neoplastic disorder comprising at least one container having a dimeric antibody that binds specifically to TAG-72 deposited therein,:

which dimeric antibody comprises two antibodies that are non-covalently associated to form a tetravalent antibody dimer,

wherein each of the antibodies in the dimer comprises two antibody heavy chain polypeptides having the heavy chain polypeptide amino acid sequence shown in Figure 4A (SEQ ID NO: 7), and two antibody light chain polypeptides having the light chain polypeptide amino acid sequence shown in Figure 5A (SEQ ID NO: 9), and has two antigen-binding sites that bind specifically to TAG-72; and

wherein a C_H2 domain is deleted from each of the four antibody heavy chain polypeptides in the dimeric antibody;

and further comprising a label or an insert indicating that said dimeric antibody may be used to treat said neoplastic disorder.

81. (New) The kit of claim 80, wherein said antibody dimer is a chimeric antibody comprising human antibody constant regions.

82. (New) The kit of claim 80, wherein said antibody dimer comprises an antibody heavy chain polypeptide in which a C_H3 domain is fused directly to the hinge region.

U.S. Patent Application No. 10/058,069
Attorney Ref. No.: 037003-0280727

83. (New) The kit of claim 80, wherein said antibody dimer comprises an antibody heavy chain polypeptide in which an amino acid spacer is inserted in place of a deleted C_H2 domain.

84. (New) The kit of claim 80 wherein said neoplastic disorder is colon cancer.

85. (New) A dimeric antibody that binds specifically to TAG-72,
which dimeric antibody comprises two antibodies that are non-covalently associated to form a tetravalent antibody dimer,

wherein each of the antibodies in the dimer comprises two antibody heavy chain polypeptides having the heavy chain polypeptide amino acid sequence shown in Figure 4A (SEQ ID NO: 7), and two antibody light chain polypeptides having the light chain polypeptide amino acid sequence shown in Figure 5A (SEQ ID NO: 9), and has two antigen-binding sites that bind specifically to TAG-72; and

wherein a C_H2 domain is deleted from each of the four antibody heavy chain polypeptides in the dimeric antibody.

86. (New) The dimeric antibody of claim 85 wherein said dimeric antibody is conjugated to a cytotoxic agent.

87. (New) The dimeric antibody of claim 85 wherein said cytotoxic agent comprises a radioisotope.

88. (New) The dimeric antibody of claim 85 wherein said radioisotope is selected from the group consisting of ⁹⁰Y, ¹²⁵I, ¹³¹I, ¹²³I, ¹¹¹In, ¹⁰⁵Rh, ¹⁵³Sm, ⁶⁷Cu, ⁶⁷Ga, ¹⁶⁶Ho, ¹⁷⁷Lu, ¹⁸⁶Re and ¹⁸⁸Re.

89. (New) The dimeric antibody of claim 86, wherein said cytotoxic agent is selected from the group consisting of cytostatic agents, alkylating agents, antimetabolites, anti-proliferative agents, tubulin binding agents, hormones and hormone antagonists, anthracycline drugs, vinca drugs, mitomycins, bleomycins, cytotoxic nucleosides, pteridine drugs, diynenes, podophyllotoxins, toxic enzymes, and radiosensitizing drugs.

90. (New) The dimeric antibody of claim 89, wherein said cytotoxic agent is selected from the group consisting of mechlorethamine, triethylenephosphoramide, cyclophosphamide, ifosfamide, chlorambucil, busulfan, melphalan, triaziquone, nitrosourea compounds, adriamycin, carminomycin, daunorubicin (daunomycin), doxorubicin, aminopterin, methotrexate, methopterin, mithramycin, streptonigrin, dichloromethotrexate, mitomycin C, actinomycin-D, porfiromycin, 5-fluorouracil, floxuridine, florafur, 6-mercaptopurine,

U.S. Patent Application No. 10/058,069
Attorney Ref. No.: 037003-0280727

cytarabine, cytosine arabinoside, podophyllotoxin, etoposide, etoposide phosphate, melphalan, vinblastine, vincristine, leurosine, vindesine, leurosine, taxol, taxane, cytochalasin B, gramicidin D, ethidium bromide, emetine, tenoposide, colchicin, dihydroxy anthracin dione, mitoxantrone, procaine, tetracaine, lidocaine, propranolol, puromycin, ricin subunit A, abrin, diphtheria toxin, botulinum, cyanginosins, saxitoxin, shigatoxin, tetanus, tetrodotoxin, trichothecene, verrucologen, corticosteroids, progestins, estrogens, antiestrogens, androgens, aromatase inhibitors, calicheamicin, esperamicins, and dynemicins.

91. (New) The dimeric antibody of claim 89, wherein said hormone or hormone antagonist is selected from the group consisting of prednisone, hydroxyprogesterone, medroprogesterone, diethylstilbestrol, tamoxifen, testosterone, and aminogluthetamide.

92. (New) The dimeric antibody of claim 86, wherein said cytotoxic agent is a prodrug selected from the group consisting of phosphate-containing prodrugs, thiophosphate-containing prodrugs, sulfate containing prodrugs, peptide containing prodrugs, β -lactam-containing prodrugs, optionally substituted phenoxyacetamide-containing prodrugs, optionally substituted phenylacetamide-containing prodrugs, 5-fluorocytosinem, and 5-fluorouridine prodrugs that can be converted to the more active cytotoxic free drug.